Login to Your Account

Discovery Labs Turns Focus to Surfaxin Market Strategy

By Marie Powers
Staff Writer

Thursday, March 8, 2012

Persistence paid off for Discovery Laboratories Inc., whose synthetic, peptide-containing surfactant Surfaxin (lucinactant intratracheal suspension) received FDA approval late Tuesday for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for the condition.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription